Boston Scientific Corporation reported robust Q3 2024 financial results with net sales reaching $4.209 billion, up 19.4% from $3.527 billion in Q3 2023. The growth included 18.2% organic growth and 130 basis points contribution from recent acquisitions. Reported net income was $469 million or $0.32 per share, while adjusted net income reached $937 million or $0.63 per share.The company's performance was primarily driven by strong commercial execution across businesses, particularly the rapid adoption of the Farapulse Pulsed Field Ablation System following its U.S. launch in early 2024. The Cardiology segment led growth with a 29.2% increase to $2.129 billion, while MedSurg segment grew 10.3% to $1.479 billion. Gross profit margin remained stable at 68.8%.Looking ahead, Boston Scientific announced plans to acquire Axonics for $3.67 billion, expected to close in Q4 2024. The company maintains a strong financial position with $2.502 billion in cash and cash equivalents, and $2.750 billion available under its revolving credit facility. Management continues to focus on strategic acquisitions and innovation while maintaining operational efficiency across its global operations.

Boston Scientific Corporation reported robust Q3 2024 financial results with net sales reaching $4.209 billion, up 19.4% from $3.527 billion in Q3 2023. The growth included 18.2% organic growth and 130 basis points contribution from recent acquisitions. Reported net income was $469 million or $0.32 per share, while adjusted net income reached $937 million or $0.63 per share.The company's performance was primarily driven by strong commercial execution across businesses, particularly the rapid adoption of the Farapulse Pulsed Field Ablation System following its U.S. launch in early 2024. The Cardiology segment led growth with a 29.2% increase to $2.129 billion, while MedSurg segment grew 10.3% to $1.479 billion. Gross profit margin remained stable at 68.8%.Looking ahead, Boston Scientific announced plans to acquire Axonics for $3.67 billion, expected to close in Q4 2024. The company maintains a strong financial position with $2.502 billion in cash and cash equivalents, and $2.750 billion available under its revolving credit facility. Management continues to focus on strategic acquisitions and innovation while maintaining operational efficiency across its global operations.